Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Assets: 2022-2025

Historic Assets for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $448.3 million.

  • Centessa Pharmaceuticals' Assets fell 26.47% to $448.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $448.3 million, marking a year-over-year decrease of 26.47%. This contributed to the annual value of $576.8 million for FY2024, which is 60.11% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Assets is $448.3 million, which was down 8.91% from $492.1 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Assets registered a high of $609.7 million during Q3 2024, and its lowest value of $328.2 million during Q1 2024.
  • Its 3-year average for Assets is $446.9 million, with a median of $403.9 million in 2023.
  • In the last 5 years, Centessa Pharmaceuticals' Assets slumped by 30.63% in 2023 and then surged by 61.57% in 2024.
  • Centessa Pharmaceuticals' Assets (Quarterly) stood at $444.3 million in 2022, then dropped by 18.92% to $360.2 million in 2023, then surged by 60.11% to $576.8 million in 2024, then declined by 26.47% to $448.3 million in 2025.
  • Its last three reported values are $448.3 million in Q3 2025, $492.1 million for Q2 2025, and $527.8 million during Q1 2025.